Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation - Poll - MDSpire

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

  • By

  • Paola Facheris

  • Francesco Piscazzi

  • Giovanni Fiorillo

  • Mario Valenti

  • Antonio Costanzo

  • Riccardo G. Borroni

  • April 24, 2026

  • 0 min

Share

Original Source(s)

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

  • by Paola Facheris, Francesco Piscazzi, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Riccardo G. Borroni

  • April 24, 2026

Related Content

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial